Tandem Diabetes Care (TNDM) Receivables - Net (2013 - 2026)

Tandem Diabetes Care (TNDM) has 14 years of Receivables - Net data on file, last reported at $147.6 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 16.61% year-over-year to $147.6 million; the trailing twelve-month figure through Mar 2026 stood at $147.6 million (up 16.61% YoY), and the FY2025 full-year result was $165.5 million, up 44.43% from the prior year.
• Receivables - Net for Q1 2026 stood at $147.6 million, down from $165.5 million in the prior quarter.
• Across five years, Receivables - Net topped out at $165.5 million in Q4 2025 and bottomed at $91.4 million in Q1 2023.
• The 5-year median for Receivables - Net is $107.2 million (2024), against an average of $114.5 million.
• The widest annual swing landed in 2023, when Receivables - Net slipped 7.99%; it then jumped 44.43% in 2025.
• A 5-year view of Receivables - Net shows it stood at $114.7 million in 2022, then decreased by 7.99% to $105.6 million in 2023, then gained by 8.55% to $114.6 million in 2024, then soared by 44.43% to $165.5 million in 2025, then retreated by 10.82% to $147.6 million in 2026.
• The last three Receivables - Net figures came in at $147.6 million (Q1 2026), $165.5 million (Q4 2025), and $133.5 million (Q3 2025), per Business Quant data.

Peer Comparison